Webinar Technology

Taking your virus production to the next level: Achieving high-quality, high-titer recombinant AAV and lentiviruses

This webinar is brought to you by the Science/AAAS Custom Publishing Office

Taking your virus production to the next level: Achieving high-quality, high-titer recombinant AAV and lentiviruses

28 November 2018

12:00 p.m. ET

Register to watch recording


Virus transduction is a common and powerful nucleic-acid delivery tool used by researchers in both the academic and private sector for numerous molecular and cell biology applications. Adeno-associated viruses (AAV) and lentiviruses are also becoming the preferred viral vector systems for gene delivery in clinical trials because of their ability to infect a variety of cell types with high efficiency for sustained gene expression or for cell-line engineering applications. Yet, these virus vectors have several shortcomings, including elaborate and labor-intensive production procedures, low packaging capacities, and variable infection rates. In addition, there is a need for current good manufacturing practices (cGMP) ancillary materials in clinical trials for production of high-quality, high-titer viruses. Effective solutions are now available to address these needs for research and biotherapeutic workflows.

During the webinar, the speakers will:

  • Discuss the benefits of virus-mediated delivery
  • Introduce applications supported by AAV/lentiviruses
  • Describe recent advances in virus production
  • Answer your questions during the live broadcast!

This webinar will last for approximately 60 minutes.

Speaker bios

Boris Kantor, Ph.D.

Duke University
Durham, NC

Dr. Kantor holds two Ph.D.’s, one he received in 1995 from the Grodno State Medical University, Republic of Belarus, and another from the Hebrew University of Jerusalem, Israel, in 2005. He has a broad background in molecular virology and gene therapy, with specific training and expertise in various viral vector platforms for gene delivery, including integrated and nonintegrated lentiviral vectors, retroviral vectors, adeno-associated vectors, and herpes simplex virus type I. He is currently an assistant research professor and director of the Viral Vector Core (VVC) in the Department of Neurobiology at the Duke University School of Medicine. Dr. Kantor’s lab creates virus-mediated tools for gene transfer, including advanced RNA interference (RNAi) and RNA-guided nucleases (RGN; CRISPR/Cas), by investigators across diverse fields of study such as systems neuroscience, stem cell biology, metabolism, aging, cancer biology, and others. Services are open to researchers within the Duke University Medical Center as well as outside investigators worldwide.

Richard O. Snyder, Ph.D.

Brammer Bio
Alachua, FL

Dr. Snyder is the chief scientific officer at Brammer Bio, a contract development and manufacturing organization providing clinical and commercial supply of viral vectors for in vivo gene therapy and ex vivo modified cell–based therapy, along with process and analytical development, and regulatory support, enabling large pharma and biotech clients to accelerate the delivery of novel medicines to improve patients’ health. He has been investigating virus biology, vector development, current good manufacturing practice (cGMP) vector manufacturing and analytical technologies, and viral vector–mediated gene transfer for over 32 years, and worked on teams who developed novel viral vector–based human gene therapies. He was an associate professor of molecular genetics and microbiology as well as director of Biotherapeutic Programs at the University of Florida; an assistant professor of pediatrics at Harvard Medical School; and was previously employed by Cell Genesys, Somatix, Merlin, and Avigen, where he helped develop gene transfer vector and vaccine technology, along with therapeutic applications. Dr. Snyder was a postdoctoral fellow at Johns Hopkins University School of Medicine, and received his doctoral degree in microbiology from the State University of New York at Stony Brook, and his B.A. in biology from Washington University in St. Louis.

Jackie Oberst, Ph.D.

Washington, D.C.

Dr. Oberst did her undergraduate training at the University of Maryland, College Park, and her Ph.D. in Tumor Biology at Georgetown University, Washington D.C. She combined her interests in science and writing by pursuing an M.A. in Journalism from the Philip Merrill College of Journalism at the University of Maryland, College Park. Dr. Oberst joined Science/AAAS in 2016 as the Assistant Editor for Custom Publishing. Before then she worked at Nature magazine, the Howard Hughes Medical Institute, The Endocrine Society, and the National Institutes of Mental Health.

Sponsored by

Get webinar alerts

For more information on upcoming webinars, recorded sessions and more, sign up for webinar alerts.

Sign up here